GELS: צמיחה צפויה ברווח למניה לשנה הבאה Gelteq
Gelteq Limited monetizes patents for gel drug delivery systems through licensing agreements with pharmaceutical manufacturers. The price action on the GURU.Markets chart, analyzed through earnings per share (EPS) forecasts, shows that 0.00 is establishing a new level. The company's technologies target the B2B market and patients with dysphagia, while expansion into veterinary medicine and sports, supported by the FDA, strengthens customer loyalty.
פילוחים אנליטיים ודוחות נתונים של חברת Gelteq (GELS)
This assessment of the forward EPS trend characterizes Gelteq Limited (GELS) as a high-tech issuer within the biopharmaceutical sector. The metric measures the expected rate of change in net income by aggregating analyst earnings forecasts for the next twelve months. For Gelteq Limited, growth in this indicator depends directly on the success of licensing agreements and the dosing precision of the new gel-based drug delivery system.
